Pharmaceutical News

RSS

Long-term study reveals safety of metformin use during pregnancy

Metformin is safe to use during pregnancy to manage diabetes, with no long-term adverse effects on the children born and their mothers for at least 11 years after childbirth, according to research presented Sunday at ENDO 2024, the Endocrine Society's annual meeting in Boston, Mass.

3 Jun 2024

Two diabetes medications more beneficial in preventing major cardiovascular events

GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data being presented Sunday at ENDO 2024, the Endocrine Society's annual meeting in Boston, Mass.

3 Jun 2024

Insurance denials hinder GLP1Ra use in children and teens with type 2 diabetes

Health insurance companies often deny coverage for new medications that treat children and teens with obesity and type 2 diabetes, meaning many patients who need treatment are unable to afford it, according to a study presented at ENDO 2024, the Endocrine Society's annual meeting in Boston, Mass.

3 Jun 2024

Weight loss drug may change how obese people perceive taste

Semaglutide improved taste sensitivity, changed gene expression in the tongue that's responsible for taste perception, and changed the brain's response to sweet tastes, according to research presented Saturday at ENDO 2024, the Endocrine Society's annual meeting in Boston, Mass.

3 Jun 2024

Tirzepatide treatment results in successful weight loss regardless of obesity-related complications

Having medical conditions linked to obesity does not impact the total weight loss achieved with the anti-obesity medication tirzepatide, according to an industry-supported study being presented Saturday at ENDO 2024, the Endocrine Society's annual meeting in Boston, Mass.

3 Jun 2024

GLP-1 drugs may reduce pancreatitis risk in obese and diabetic patients

Medications for type 2 diabetes and obesity known as GLP-1 receptor agonists may lower the risk of acute pancreatitis recurrence in people with obesity and those with type 2 diabetes, according to a study presented Saturday at ENDO 2024, the Endocrine Society's annual meeting in Boston, Mass.

3 Jun 2024

Progesterone therapy shows mixed results for neurodevelopment in infants with heart defects

A randomized clinical trial published in JAMA Network Open found no significant overall benefit of maternal progesterone therapy on neurodevelopmental outcomes in infants with congenital heart defects, but observed improvements in female children and specific heart conditions.

2 Jun 2024

Community pharmacists deliver cheaper, quality care for minor ailments, study shows

A recent study in ClinicoEconomics and Outcomes Research found that community pharmacists can provide high-quality, cost-effective care for minor ailments, reducing the financial burden on the healthcare system compared to primary care physicians, urgent care, and emergency departments.

2 Jun 2024

RNA interference agent plozasiran targets APOC3 for effective mixed hyperlipidemia treatment

Researchers evaluate the efficacy of plazosiran treatment on fasting triglyceride levels in adult patients with mixed hyperlipidemia.

31 May 2024

Study examines the cost-effectiveness of a targeted immunotherapy for lung cancer

Many countries with national healthcare systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health benefits.

30 May 2024

Study examines prescribing patterns of tricyclic antidepressants for treatment of diabetic peripheral neuropathy

Many adults with diabetes and the associated complication of peripheral neuropathy, which can be painful as well as harmful, are often prescribed drugs at doses and for durations that could impose an increased risk of cognitive impairment.

30 May 2024

Existing drug alleviates symptoms of a rare genetic syndrome

A drug approved to treat certain autoimmune diseases and cancers successfully alleviated symptoms of a rare genetic syndrome called autoimmune polyendocrine syndrome type 1 (APS-1).

30 May 2024

An obscure drug discount program stifles use of federal lifeline by rural hospitals

Facing ongoing concerns about rural hospital closures, Capitol Hill lawmakers have introduced a spate of proposals to fix a federal program created to keep lifesaving services in small towns nationwide.

30 May 2024

Could edible robots be the future of food and medicine?

A review in Nature Reviews Materials explores the potential of edible materials in creating robotic foods and edible robots, highlighting their therapeutic and environmental benefits, while addressing current research challenges.

29 May 2024

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

A recent study in the Journal of Clinical Medicine found that oral semaglutide significantly improves glycemic control and reduces body weight in type 2 diabetes patients after 24 weeks of treatment.

29 May 2024

New antibiotic lolamicin shows promise in fighting drug-resistant infections

Researchers have developed a new antibiotic that reduced or eliminated drug-resistant bacterial infections in mouse models of acute pneumonia and sepsis while sparing healthy microbes in the mouse gut.

29 May 2024

Psychoactive drugs are having a moment. The FDA will soon weigh in.

Lori Tipton is among the growing number of people who say that MDMA, also known as ecstasy, saved their lives.

29 May 2024

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

Secarna Pharmaceuticals GmbH & Co. KG (Secarna), a leading independent European antisense drug discovery and development company, and Orbit Discovery Ltd. (Orbit), a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.

From Secarna Pharmaceuticals 29 May 2024

New Alzheimer's drug LM11A-31 shows promise in slowing disease progression in clinical trial

A recent study in Nature Medicine found that LM11A-31, targeting the p75 neurotrophin receptor, is safe and shows promise in slowing Alzheimer's disease progression. The trial indicated significant biomarker improvements and potential benefits for further clinical investigation.

28 May 2024

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular disease by 22%. The SELECT trial results highlight semaglutide's benefits for kidney function and overall cardiovascular health.

28 May 2024

Previous
1
...
24
25
26
27
28
29
30
...
1443
Next

Pharmaceutical News

Long-term study reveals safety of metformin use during pregnancy

Two diabetes medications more beneficial in preventing major cardiovascular events

Insurance denials hinder GLP1Ra use in children and teens with type 2 diabetes

Weight loss drug may change how obese people perceive taste

Tirzepatide treatment results in successful weight loss regardless of obesity-related complications

GLP-1 drugs may reduce pancreatitis risk in obese and diabetic patients

Progesterone therapy shows mixed results for neurodevelopment in infants with heart defects

Community pharmacists deliver cheaper, quality care for minor ailments, study shows

RNA interference agent plozasiran targets APOC3 for effective mixed hyperlipidemia treatment

Study examines the cost-effectiveness of a targeted immunotherapy for lung cancer

Study examines prescribing patterns of tricyclic antidepressants for treatment of diabetic peripheral neuropathy

Existing drug alleviates symptoms of a rare genetic syndrome

An obscure drug discount program stifles use of federal lifeline by rural hospitals

Could edible robots be the future of food and medicine?

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

New antibiotic lolamicin shows promise in fighting drug-resistant infections

Psychoactive drugs are having a moment. The FDA will soon weigh in.

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

New Alzheimer's drug LM11A-31 shows promise in slowing disease progression in clinical trial

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News